Androgen deprivation therapy (ADT ... or biochemical relapse of prostate cancer (PC). Bone mineral density (BMD) loss is rapid during the first year of ADT; up to 4.6% of total hip, femoral ...

Almost all prostate cancer patients become resistant to therapy that blocks androgen-mediated cell proliferation. The key to this resistance may lie in expression of the androgen receptor itself.

Researchers have identified a new role for the enzyme EZH2 in promoting the progression of aggressive, treatment-resistant ...

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, according to a new study. The results could potentially lead to new therapies ...

On International Men's Day, the Clinical Trials Arena team investigates three therapies being investigated in prostate cancer ...

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, ...

Patients with nmCRPC have a lower risk of treatment discontinuation and disease progression if they receive darolutamide, data suggest.

Scientists at Weill Cornell Medicine have uncovered a critical mechanism driving the growth of treatment-resistant prostate ...

Dr. Scott Tagawa presented ProstACT GLOBAL, a phase III study of best SOC with or without 177 Lu-DOTA-rosopatamab (TLX591) for patients with PSMA-expressing mCRPC who experienced disease progression ...

ONCOLife proudly presents an exclusive interview with Dr. Iris Kuss, VP and Global Development Lead Oncology at Bayer. In ...

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, according to a new study by scientists at Weill Cornell Medicine.

Bayer BAYRY announced that the FDA has accepted its supplemental new drug application (sNDA) for Nubeqa (darolutamide). The ...